{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:27:46Z","timestamp":1789705666955,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Falciparum malaria remains one of the deadliest infectious diseases worldwide. In Germany, it is mainly an imported infection among travellers. Rates of coinfection are often unknown, and a clinical rationale for the beneficial use of calculated antibiotic therapy in patients with malaria and suspected coinfection is lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted an analysis of all in-patients treated with falciparum malaria at a German infectious diseases centre in vicinity to one of Europe\u2019s major airports for 2010\u20132019. Logistic regression and time-to-event analysis were used to evaluate predictors for bacterial coinfection, the use of antibacterial substances, as well as their influence on clinical course.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 264 patients were included. Of those, 64% received an additional antibacterial therapy (<jats:italic>n<\/jats:italic>\u2009=\u2009169). Twenty-nine patients (11.0%) were found to have suffered from a relevant bacterial coinfection, while only a small fraction had relevant bacteremia (<jats:italic>n<\/jats:italic>\u2009=\u20093, 1.4%). However, patients with severe malaria did not suffer from coinfections more frequently (<jats:italic>p<\/jats:italic>\u2009=\u20090.283). CRP levels were not a reliable predictor for a bacterial coinfection (OR 0.99, 95% CI 0.94\u20131.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.850), while another clinical focus of infection was positively associated (OR 3.86, 95% CI 1.45\u201311.55, <jats:italic>p<\/jats:italic> \u2009=\u20090.010).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although bacterial coinfections were rare in patients with malaria at our centre, the risk does not seem negligible. These data point rather towards individual risk assessment in respective patients than to general empiric antibiotic use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-023-02103-x","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:03:21Z","timestamp":1698404601000},"page":"461-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Coinfections and antimicrobial treatment in a cohort of falciparum malaria in a non-endemic country: a 10-year experience"],"prefix":"10.1007","volume":"52","author":[{"given":"Claus P.","family":"K\u00fcpper-Tetzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundolf","family":"Sch\u00fcttfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hoehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Kohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hogardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Besier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Wichelhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Wetzstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"2103_CR1","unstructured":"WHO Guidelines for malaria. WHO Guidelines for malaria. World Health Organization; 2021. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33724744. Accessed 29 Mar 2021"},{"key":"2103_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2021.691095","author":"MA Boualam","year":"2021","unstructured":"Boualam MA, Pradines B, Drancourt M, Barbieri R. Malaria in Europe: A Historical Perspective. Front Med. 2021. https:\/\/doi.org\/10.3389\/FMED.2021.691095.","journal-title":"Front Med"},{"key":"2103_CR3","unstructured":"Rapid risk assessment: Multiple reports of locally-acquired malaria infections in the EU.  https:\/\/www.ecdc.europa.eu\/en\/publications-data\/rapid-risk-assessment-multiple-reports-locally-acquired-malaria-infections-eu. Accessed 20 Jan 2023"},{"key":"2103_CR4","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2020. 2020."},{"key":"2103_CR5","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2011. 2012."},{"key":"2103_CR6","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2015.2016."},{"key":"2103_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00104-19","author":"J Mischlinger","year":"2020","unstructured":"Mischlinger J, R\u00f6nnberg C, \u00c1lvarez-Mart\u00ednez MJ, B\u00fchler S, Paul M, Schlagenhauf P, et al. Imported malaria in countries where malaria is not endemic: a comparison of semi-immune and nonimmune travelers. Clin Microbiol Rev. 2020. https:\/\/doi.org\/10.1128\/CMR.00104-19.","journal-title":"Clin Microbiol Rev"},{"key":"2103_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.tmaid.2010.01.003","volume":"8","author":"A Pavli","year":"2010","unstructured":"Pavli A, Maltezou HC. Malaria and travellers visiting friends and relatives. Travel Med Infect Dis. 2010;8:161\u20138. https:\/\/doi.org\/10.1016\/j.tmaid.2010.01.003.","journal-title":"Travel Med Infect Dis"},{"key":"2103_CR9","doi-asserted-by":"publisher","unstructured":"Wieters I, Eisermann P, Borgans F, Giesbrecht K, Goetsch U, Just-Nubling G, et al. Two cases of airport-associated falciparum malaria in Frankfurt am Main, Germany, October 2019. In: Eurosurveillance. European Centre for Disease Prevention and Control (ECDC); 2019. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.49.1900691.","DOI":"10.2807\/1560-7917.ES.2019.24.49.1900691"},{"key":"2103_CR10","unstructured":"Malaria - Annual Epidemiological Report for 2019. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/malaria-annual-epidemiological-report-2019.  Accessed 20 Jan 2023"},{"key":"2103_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac002","author":"D Camprub\u00ed-Ferrer","year":"2022","unstructured":"Camprub\u00ed-Ferrer D, Cobuccio L, Van Den Broucke S, Genton B, Bottieau E, D\u2019acremont V, et al. Causes of fever in returning travelers: a European multicenter prospective cohort study. J Travel Med. 2022. https:\/\/doi.org\/10.1093\/jtm\/taac002.","journal-title":"J Travel Med"},{"key":"2103_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12879-015-1272-6","volume":"15","author":"Y Lubell","year":"2015","unstructured":"Lubell Y, Blacksell SD, Dunachie S, Tanganuchitcharnchai A, Althaus T, Watthanaworawit W, et al. Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia. BMC Infect Dis. 2015;15:511. https:\/\/doi.org\/10.1186\/s12879-015-1272-6.","journal-title":"BMC Infect Dis"},{"key":"2103_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/0035-9203(93)90279-Y","volume":"87","author":"TJD O\u2019Dempsey","year":"1993","unstructured":"O\u2019Dempsey TJD, McArdle TF, Laurence BE, Todd JE, Greenwood BM, Lamont AC. Overlap in the clinical features of pneumonia and malaria in African children. Trans R Soc Trop Med Hyg. 1993;87:662\u20135. https:\/\/doi.org\/10.1016\/0035-9203(93)90279-Y.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2103_CR14","unstructured":"Leitlinie: Diagnostik und Therapie der Malaria. 2021. www.dtg.org. Accessed 24 Jan 2023"},{"key":"2103_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1128\/JCM.02149-12","volume":"51","author":"J Sandlund","year":"2013","unstructured":"Sandlund J, Naucler P, Dashti S, Shokri A, Eriksson S, Hjertqvist M, et al. Bacterial coinfections in travelers with malaria: Rationale for antibiotic therapy. J Clin Microbiol. 2013;51:15\u201321. https:\/\/doi.org\/10.1128\/JCM.02149-12.","journal-title":"J Clin Microbiol"},{"key":"2103_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/J.IJANTIMICAG.2017.12.013","volume":"51","author":"E Carrara","year":"2018","unstructured":"Carrara E, Pfeffer I, Zusman O, Leibovici L, Paul M. Determinants of inappropriate empirical antibiotic treatment: systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51:548\u201353. https:\/\/doi.org\/10.1016\/J.IJANTIMICAG.2017.12.013.","journal-title":"Int J Antimicrob Agents"},{"key":"2103_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003543.PUB4","author":"P Davey","year":"2017","unstructured":"Davey P, Marwick CA, Scott CL, Charani E, Mcneil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.CD003543.PUB4.","journal-title":"Cochrane Database Syst Rev"},{"key":"2103_CR18","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2018. https:\/\/www.r-project.org\/."},{"key":"2103_CR19","doi-asserted-by":"crossref","unstructured":"Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016. https:\/\/ggplot2.tidyverse.org.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"2103_CR20","doi-asserted-by":"crossref","unstructured":"Kahle D, Wickham H. ggmap: Spatial Visualization with ggplot2. R J. 2013;5: 144\u2013161. https:\/\/journal.r-project.org\/archive\/2013-1\/kahle-wickham.pdf.","DOI":"10.32614\/RJ-2013-014"},{"key":"2103_CR21","unstructured":"Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using \u201cggplot2.\u201d 2019. https:\/\/cran.r-project.org\/package=survminer."},{"key":"2103_CR22","unstructured":"Therneau TM. A Package for Survival Analysis in S. 2015. https:\/\/cran.r-project.org\/package=survival."},{"key":"2103_CR23","unstructured":"Harrison E, Drake T, Ots R. finalfit: Quickly Create Elegant Regression Results Tables and Plots when Modelling. 2022. https:\/\/github.com\/ewenharrison\/finalfit."},{"key":"2103_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1378\/CHEST.11-2655","volume":"142","author":"WRJ Taylor","year":"2012","unstructured":"Taylor WRJ, Hanson J, Turner GDH, White NJ, Dondorp AM. Respiratory manifestations of malaria. Chest. 2012;142:492\u2013505. https:\/\/doi.org\/10.1378\/CHEST.11-2655.","journal-title":"Chest"},{"key":"2103_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/J.PT.2013.04.006","volume":"29","author":"PE Van den Steen","year":"2013","unstructured":"Van den Steen PE, Deroost K, Deckers J, Van Herck E, Struyf S, Opdenakker G. Pathogenesis of malaria-associated acute respiratory distress syndrome. Trends Parasitol. 2013;29:346\u201358. https:\/\/doi.org\/10.1016\/J.PT.2013.04.006.","journal-title":"Trends Parasitol"},{"key":"2103_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.VIROL.2020.01.015","volume":"543","author":"P Pielnaa","year":"2020","unstructured":"Pielnaa P, Al-Saadawe M, Saro A, Dama MF, Zhou M, Huang Y, et al. Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. Virology. 2020;543:34\u201342. https:\/\/doi.org\/10.1016\/J.VIROL.2020.01.015.","journal-title":"Virology"},{"key":"2103_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10096-019-03472-8","volume":"38","author":"D Van den Bossche","year":"2019","unstructured":"Van den Bossche D, Michiels J, Cnops L, Foque N, Meersman K, Huits R, et al. Challenges in diagnosing Zika\u2014experiences from a reference laboratory in a non-endemic setting. Eur J Clin Microbiol Infect Dis. 2019;38:771\u20138. https:\/\/doi.org\/10.1007\/s10096-019-03472-8.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2103_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2019.05.004","volume":"95","author":"Y Van der Beken","year":"2019","unstructured":"Van der Beken Y, De Geyter D, Van Esbroeck M. Performance evaluation of the Diasorin LIAISON\u00ae XL Zika capture IgM CLIA test. Diagn Microbiol Infect Dis. 2019;95:144\u20138. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.004.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2103_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176708","author":"NG Schwarz","year":"2017","unstructured":"Schwarz NG, Mertens E, Winter D, Maiga-Ascofare O, Dekker D, Jansen S, et al. No serological evidence for Zika virus infection and low specificity for anti-Zika virus ELISA in malaria positive individuals among pregnant women from Madagascar in 2010. PLoS ONE. 2017. https:\/\/doi.org\/10.1371\/journal.pone.0176708.","journal-title":"PLoS ONE"},{"key":"2103_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4269\/AJTMH.1991.44.571","volume":"44","author":"DM Banic","year":"1991","unstructured":"Banic DM, Viana-Martins FS, De Souza JM, De Castro PT, Daniel-Ribeiro C. Polyclonal B-lymphocyte stimulation in human malaria and its association with ongoing parasitemia. Am J Trop Med Hyg. 1991;44:571\u20137. https:\/\/doi.org\/10.4269\/AJTMH.1991.44.571.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02103-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T09:57:28Z","timestamp":1710928648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02103-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02103-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Claus P. K\u00fcpper-Tetzel, Johanna Kessel, Niko Kohmer, Silke Besier, and Nils Wetzstein have nothing to disclose. Raja Idris received speaker fees from Tillotts Pharma GmbH. Gundolf Sch\u00fcttfort received funding from Gilead Sciences and speaker fees from ViiV Healthcare, Bristol Meyer Squibb, MSD and Hormosan for participation in Advisory Boards, Data Safety and Monitoring Boards and for preparation of educational materials and lecturing fees. Christiana Graf received travel grands and fees for advisory board services from AbbVie Deutschland GmbH & Co and Gilead Sciences GmbH. Michael Hogardt reports grants from Mukoviszidose Institut gGmbH and the German Federal Ministry of Health, honoraria for lectures from the Landes\u00e4rztekammer Hessen, bioM\u00e9rieux, Pfizer Pharma and funding from Merck AG outside the submitted work. Sebastian Hoehl received study support from Roche diagnostics. Thomas A. Wichelhaus reports research grants from MSD, Deutsche Krebshilfe, as well as speaker fees and consulting honoraria from Insmed, Osartis, all outside the submitted work. Maria J.G.T. Vehreschild received research grants from 3M, Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck\/MSD, Organobalance, Seres Therapeutics, Takeda Pharmaceutical, as well as speaker fees or consulting fees from Alb Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Basilea, Bio-M\u00e9rieux, DaVolterra, Farmak International Holding GmbH, Ferring, Gilead Sciences, Immunic AG, MaaT Pharma, Merck\/MSD, Pfizer, Roche, Organobalance, SocraTec R&D GmbH, Tillots Pharma GmbH. Christoph Stephan has received fees for lectures and\/or advisory board services from Gilead sciences, Janssen-Cilag, MSD & ViiV healthcare, and travel grants for scientific conference attendance from Gilead, Janssen, and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by our local ethics committee under file number 20\u20131009.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}